BIOKAD, AO

🇷🇺Russia
Ownership
-
Employees
-
Market Cap
-
Website
globenewswire.com
·

Growth Trends in the CRISPR and Cas Gene Market: Industry

The CRISPR and Cas gene market was valued at $3.3 billion in 2023, with a CAGR of 20.38% since 2018. It's projected to reach $8.8 billion by 2028 and $24.6 billion by 2033. Growth drivers include personalized medicine, genetic disorders, and synthetic biology. Challenges include regulatory complexities and healthcare access in developing countries. The market is segmented by type, application, product type, end use, and service type, with various segments showing significant growth potential. North America leads the market, but Asia-Pacific and Africa are expected to grow fastest. The market is dominated by large players like Danaher Corporation and Agilent Technologies Inc.
prnewswire.com
·

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.
einpresswire.com
·

Key Trastuzumab Biosimilars Market Trend 2024-2033: Focus on New Product Launches

Trastuzumab biosimilars market to grow from $4.27B in 2023 to $5.43B in 2024, reaching $14.69B by 2028, driven by market expansion, patent expirations, and competitive pricing.
finance.yahoo.com
·

Global Cancer Gene Therapy Market Set for Significant Growth, Projected to Reach USD ...

The global cancer gene therapy market is projected to grow from USD 1,822.2 million in 2024 to USD 3,142.2 million by 2034, driven by increased R&D funding, rising cancer prevalence, and favorable government regulations. Oncolytic virotherapy, a key segment, generated USD 850.7 million in 2023. The market is shifting towards personalized, targeted therapies, reducing side effects and improving outcomes.
openpr.com
·

Hemophilia B Clinical Trials 2024: EMA, PDMA, FDA Approvals

DelveInsight's 'Hemophilia B Pipeline Insight, 2024' report details the global Hemophilia B treatment market, including clinical trials, therapies, and company developments. Key companies and therapies in various stages of development are highlighted, along with market drivers and barriers.
© Copyright 2024. All Rights Reserved by MedPath